Literature DB >> 10868279

Transient host range selection for genetic engineering of modified vaccinia virus Ankara.

C Staib1, I Drexler, M Ohlmann, S Wintersperger, V Erfle, G Sutter.   

Abstract

Recombinant vaccinia viruses are extremely valuable tools for research in molecular biology and immunology. The extension of vaccinia vector technology to replication-deficient and safety-tested virus strains such as modified vaccinia virus Ankara (MVA) have made this versatile eukaryotic expression system even more attractive for basic and clinical research. Here, we report on easily obtaining recombinant MVA using stringent growth selection on rabbit kidney RK-13 cells. We describe the construction and use of new MVA vector plasmids that carry an expression cassette of the vaccinia virus host range gene, K1L, as a transient selectable marker. These plasmids allow either stable insertion of additional recombinant genes into the MVA genome or precisely targeted mutagenesis of MVA genomic sequences. Repetitive DNA sequences flanking the K1L gene were designed to remove the marker gene from the viral genome by homologous recombination under nonselective growth conditions. The convenience of this new selection technique is demonstrated by isolating MVA recombinants that produce green fluorescent protein and by generating MVA deletion mutants.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10868279     DOI: 10.2144/00286st04

Source DB:  PubMed          Journal:  Biotechniques        ISSN: 0736-6205            Impact factor:   1.993


  26 in total

1.  Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

Authors:  Zhongde Wang; Corinna La Rosa; Zhongqi Li; Heang Ly; Aparna Krishnan; Joy Martinez; William J Britt; Don J Diamond
Journal:  Vaccine       Date:  2006-10-06       Impact factor: 3.641

2.  Interference with SAMHD1 Restores Late Gene Expression of Modified Vaccinia Virus Ankara in Human Dendritic Cells and Abrogates Type I Interferon Expression.

Authors:  Katja Sliva; Judith Martin; Christine von Rhein; Tobias Herrmann; Anastasia Weyrich; Masako Toda; Barbara S Schnierle
Journal:  J Virol       Date:  2019-10-29       Impact factor: 5.103

3.  Poxviral regulation of the host NF-kappaB response: the vaccinia virus M2L protein inhibits induction of NF-kappaB activation via an ERK2 pathway in virus-infected human embryonic kidney cells.

Authors:  Roderick Gedey; Xiao-Lu Jin; Olivia Hinthong; Joanna L Shisler
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

4.  Deletion of the K1L Gene Results in a Vaccinia Virus That Is Less Pathogenic Due to Muted Innate Immune Responses, yet Still Elicits Protective Immunity.

Authors:  Ariana G Bravo Cruz; Aiguo Han; Edward J Roy; Arielle B Guzmán; Rita J Miller; Elizabeth A Driskell; William D O'Brien; Joanna L Shisler
Journal:  J Virol       Date:  2017-07-12       Impact factor: 5.103

5.  Deletion of Fifteen Open Reading Frames from Modified Vaccinia Virus Ankara Fails to Improve Immunogenicity.

Authors:  Naif Khalaf Alharbi; Alexandra J Spencer; Adrian V S Hill; Sarah C Gilbert
Journal:  PLoS One       Date:  2015-06-08       Impact factor: 3.240

Review 6.  Reflections on the early development of poxvirus vectors.

Authors:  Bernard Moss
Journal:  Vaccine       Date:  2013-04-10       Impact factor: 3.641

7.  The orthopoxvirus 68-kilodalton ankyrin-like protein is essential for DNA replication and complete gene expression of modified vaccinia virus Ankara in nonpermissive human and murine cells.

Authors:  Karin M Sperling; Astrid Schwantes; Caroline Staib; Barbara S Schnierle; Gerd Sutter
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

8.  Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L.

Authors:  Simone Hornemann; Olof Harlin; Caroline Staib; Sigrid Kisling; Volker Erfle; Bernd Kaspers; Georg Häcker; Gerd Sutter
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

9.  The vaccinia virus K1L gene product inhibits host NF-kappaB activation by preventing IkappaBalpha degradation.

Authors:  Joanna L Shisler; Xiao-Lu Jin
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

10.  Induced bronchus-associated lymphoid tissue serves as a general priming site for T cells and is maintained by dendritic cells.

Authors:  Stephan Halle; Hélène C Dujardin; Nadja Bakocevic; Henrike Fleige; Heike Danzer; Stefanie Willenzon; Yasemin Suezer; Günter Hämmerling; Natalio Garbi; Gerd Sutter; Tim Worbs; Reinhold Förster
Journal:  J Exp Med       Date:  2009-11-16       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.